Omnicell (OMCL)
(Delayed Data from NSDQ)
$27.47 USD
-0.22 (-0.79%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $27.49 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Omnicell (OMCL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$33.33 | $39.00 | $26.00 | 20.37% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Omnicell comes to $33.33. The forecasts range from a low of $26.00 to a high of $39.00. The average price target represents an increase of 20.37% from the last closing price of $27.69.
Analyst Price Targets (6 )
Broker Rating
Omnicell currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.50 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, three are Strong Buy, representing 37.5% of all recommendations. A month ago, Strong Buy represented 37.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 0 |
ABR | 2.50 | 2.50 | 2.50 | 2.50 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/9/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
1/19/2024 | BTIG | David M Larsen | Hold | Hold |
11/4/2023 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
10/11/2023 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 8 |
Average Target Price | $33.33 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | 0.12 |